Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1998-03-31
1999-07-13
Ramsuer, Robert W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
568190, 562 15, A61K 3166, C07F 938, C07F 940
Patent
active
059226978
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to compounds that inhibit the binding of proteins containing an SH2 domain to cognate phosphorylated proteins. This invention also relates to pharmaceutical compositions containing the compounds and to therapeutic methods that use the compounds.
BACKGROUND OF THE INVENTION
Many of the signal transduction pathways that regulate a variety of cellular processes, including the differentiation and proliferation of normal and malignant cells, operate through phosphorylated proteins called tyrosine kinases. The two major types of tyrosine kinases are receptor and nonreceptor tyrosine kinases.
Receptor tyrosine kinases contain binding sites or receptors for growth factors such as epidermal growth factor (EGF) or platelet-derived growth factor (PDGF). When a growth factor such as EGF or PDGF binds to the receptor, the tyrosine kinase receptor protein is activated; the tyrosine kinase receptor protein is autophosphorylated; and endogenous proteins that participate in the signal transduction pathway are phosphorlyated.
Some endogenous proteins that are involved in the cellular signal transduction pathways contain a specific domain called the SH2 domain, which provides for interaction with an activated tyrosine kinase receptor protein. This interaction is a protein-protein interaction. One protein that contains an SH2 domain is pp60c-src kinase, which is also a tyrosine kinase. The pp60c-src kinase is a nonreceptor kinase and is related to a number of nonreceptor tyrosine kinases, which include, but are not limited to, Fyn, Lck, Yes, Blk, Lyn, Fgr, Hck, and Yrk. Another important protein that contains an SH2 domain is Abl.
The pp60c-src protein is exemplary of the Src family of tyrosine kinases. The pp60c-src has three major domains: SH1, SH2, and SH3. The SH1 domain is most commonly called the catalytic domain or tyrosine kinase domain. The SH3 domain is a binding region for proteins having proline-rich sequences. Both the SH2 and SH3 domains are noncatalytic, but are important in protein-protein recognition.
The Src family of protein kinases, which all contain a SH2 domain, are involved in a number of cellular signalling pathways. For example, Src is involved in growth factor receptor signalling; integrin-mediated signaling; T- and B-cell activation and osteoclast activation. It is known that the Src SH2 domain binds to several key receptor and nonreceptor tyrosine kinases such as tyrosine kinases containing receptors for PDGF, EGF, HER2/Neu (an oncogene form of EGF), Fibroblast growth factor, focal adhesion kinase, p130 protein, and p68 protein. In addition, pp60c-src has been shown to be involved in the regulation of DNA synthesis, mitosis, and other cellular activities.
Thus, it would be useful to have compounds that inhibit the binding of proteins containing an SH2 domain to cognate phosphorylated proteins, as the inhibition of binding of proteins containing an SH2 domain to cognate phosphorylated proteins can be used to treat proliferative diseases such as cancer, osteoporosis, inflammation, allergy, restenosis, and cardiovascular disease, which all rely on signal transduction involving proteins that contain an SH2 domain that binds to phosphorylated proteins during the cellular signalling process.
SUMMARY OF THE INVENTION
The present invention provides compounds having the Formula I ##STR1## wherein
U is --CO--, --CS--, --SO--, or --SO.sub.2 ;
Y is ##STR2## or a bond;
R.sup.1 is hydrogen, RCONR'--, RR'NCONR"--, RSO.sub.2 NR'--, RCSNR'--, RR'NCSNR"--, RR'NSO.sub.2 NR"--, ROCONR'--, or ##STR3##
R.sup.2 is hydrogen, alkyl, cycloalkyl-(CH.sub.2).sub.n --, substituted alkyl, aryl-(CH.sub.2).sub.n --, heteroaryl-(CH.sub.2).sub.n --, --(CH.sub.2).sub.n --CO.sub.2 H, substituted cycloalkyl-(CH.sub.2).sub.n --, substituted aryl-(CH.sub.2).sub.n --, or substituted heteroaryl-(CH.sub.2).sub.n --;
R.sup.3 is hydrogen, alkyl, cycloalkyl-(CH.sub.2).sub.n --, substituted alkyl, aryl-(CH.sub.2).sub.n --, heteroaryl-(CH.sub.2).sub.n --, --(CH.sub.2).sub.n --CO.sub.2 H, subst
REFERENCES:
patent: 4853476 (1989-08-01), Petrakis et al.
patent: 5100654 (1992-03-01), Pawelek et al.
patent: 5162311 (1992-11-01), Herrling et al.
patent: 5175153 (1992-12-01), Bigge et al.
patent: 5190921 (1993-03-01), Roques et al.
patent: 5439819 (1995-08-01), Littman et al.
patent: 5580979 (1996-12-01), Bachovchin
Songyang, Z., et al, "SH2 Domains Recognize Specific Phosphopeptide Sequences" Cell, Mar. 12, 1993, vol. 72:767-778.
Bilder, G.E., et al., "PDGF-Receptor Protein Tyrosine Kinase Activity (R-PTKA) in Carotoid Artery in Enhanced by Injury and Inhibited In Vivo by Tyrphostin RG 13291" Supplement to Circulation, Abstracts from the 65.sup.th Scientific Sessions, New Orleans, LA on Nov. 16-19, 1992, vol. 86, No. 4, Oct. 1992, Abstract 0675.
Bilder, G.E., et al, "Tyrosine Kinase Inhibitor (TKI), RG13291 Prevents Association of .beta.-PDGF Receptor (.beta.-PDGF-R) with P13Kinase in Vascular Smooth Muscle Cells (VSCM)" Supplement to Circulation, Abstracts form the 65.sup.th Scientific Sessions, New Orleans, LA, on Nov. 16-19, 1992, vol. 86, No. 4, Oct. 1992, Abstract 1160.
Graber, M., et al., "The Protein Tyrosine Kinase Inhibitor Herbimycin A, but not Genistein, Specifically Inhibits Signal Transduction by the T-cell Antigen Receptor" International Immunology, Jun. 1992, vol. 4, No. 11, 1201-1210.
Cohen, D.I. et al., "Participation of Tyrosine Phosphorylation in the Cytopathic Effect of Human Immunodeficiency Virus-1" Science, Apr. 1992, vol. 256:542-545.
Beaulieu, A.D., et al., "Nuclear Signaling in Human Neutrophils" J of Bio Chem, Jan. 5, 1992, vol. 267, No. 1: 426-432.
Eiseman, E. & Bolen, J.B., "Engagement of the High-affinity IgE Receptor Activates scr Protein-related Tyrosine Kinases" Letters to Nature, Jan. 2, 1992, vol. 355:78-80.
Margolis, B., "Proteins with SH2 Domains: Transducers in the Tyrosine Kinase Signaling Pathway" Cell Growth & Differention, Jan. 1992, vol. 3:73-80.
Glenney, J.R., Jr., "Tyrosine-phoshorylated Proteins: Mediators of Signal transduction from the Tyrosine Kinases" 1992, Biochimica et Biophysica Acta, 1134:113-127.
Paolini, R., et al., "Phosphorylation and Dephosphorylation of the High-affinity Receptor for Immunoglobulin E Immediately after Receptor Engagement and Disengagement" Oct. 31, 1991, Nature, vol. 353:855-858.
McColl, S.R., et al., "Involvement of Tyrosine Kinases in the Activation of Human Peripheral Blood Neutrophils by Granulocyte-Macrophage Colony-Stimulating Factor" Oct. 1, 1991, Blood, vol. 78, No. 7:1842-1852.
Dvir, A., et al., "The Inhibition of EGF-dependent Proliferation of Keratinocytes by Tryphostin Tyrosine Kinase Blockers" May 1991, J of Cell Biology, vol. 113, No. 4:857-865.
Cooke, M.P., et al., "Regulation of T Cell Receptor Signaling by a src Family Protien-Tyrosine Kinase (p59.sup.fyn)" Apr. 19, 1991, Cell, vol. 65, 281-291.
Bilder, G.E., et al. "Tyrphostins Inhibits PDGF-induced DNA Synthesis and Associated Early Events in Smooth Muscle Cells" 1991, Am J Physiol, 260:C721-C730.
June, C.H., et al., "Inhibition of Tyrosine Phosphorylation Prevents T-cell Receptor -mediated Signal Transduction" Oct. 1990, Proc Natl Acad Sci USA, vol. 87:7722-7726.
Lunney Elizabeth A.
Para Kimberly S.
Plummer Mark S.
Prasad Josyula V. N. V.
Saltiel Alan R.
Crissey Todd M.
Ramsuer Robert W.
Warner-Lambert & Company
LandOfFree
Compounds, compositions and methods for inhibiting the binding o does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, compositions and methods for inhibiting the binding o, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds, compositions and methods for inhibiting the binding o will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2275854